Review





Similar Products

78c  (MedChemExpress)
94
MedChemExpress 78c
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
78c, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+inhibitor+1/pmc13669683-309-7-8
Average 94 stars, based on 1 article reviews
78c - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
compound 78c  (TargetMol)
94
TargetMol compound 78c
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Compound 78c, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+inhibitor+1/pmc13000301-348-0-19
Average 94 stars, based on 1 article reviews
compound 78c - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd38 inhibitor 78c  (MedChemExpress)
94
MedChemExpress cd38 inhibitor 78c
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Cd38 Inhibitor 78c, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+inhibitor+1/pm42814413-242-21-26
Average 94 stars, based on 1 article reviews
cd38 inhibitor 78c - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd38 inhibitors  (Specific Diagnostics)
86
Specific Diagnostics cd38 inhibitors
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Cd38 Inhibitors, supplied by Specific Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/cd38+inhibitors/pm41812700-139-15-7
Average 86 stars, based on 1 article reviews
cd38 inhibitors - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
t6273 cd38 inhibitor 78c targetmol  (TargetMol)
94
TargetMol t6273 cd38 inhibitor 78c targetmol
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
T6273 Cd38 Inhibitor 78c Targetmol, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/Vadimezan/pm41529690-168-89-93
Average 94 stars, based on 1 article reviews
t6273 cd38 inhibitor 78c targetmol - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd38 inhibitor 78c  (TargetMol)
94
TargetMol cd38 inhibitor 78c
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Cd38 Inhibitor 78c, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+inhibitor+1/pm41529690-189-90-93
Average 94 stars, based on 1 article reviews
cd38 inhibitor 78c - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cd38 inhibitor screening assay kit  (BPS Bioscience)
92
BPS Bioscience cd38 inhibitor screening assay kit
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Cd38 Inhibitor Screening Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+Inhibitor+Screening+Assay+Kit/us12514858-1747-1-6
Average 92 stars, based on 1 article reviews
cd38 inhibitor screening assay kit - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
cd38 cx43 inhibitor derived monocytes  (Tocris)
93
Tocris cd38 cx43 inhibitor derived monocytes
Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or <t>78c</t> from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.
Cd38 Cx43 Inhibitor Derived Monocytes, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+inhibitor/CD38+inhibitor/pm41350705-65-21-27
Average 93 stars, based on 1 article reviews
cd38 cx43 inhibitor derived monocytes - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or 78c from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.

Journal: Advanced Science

Article Title: Bone Marrow Macrophage STING Signaling is a Direct Nexus Linking Marrow Adipose Expansion to NAD + Depletion and Osteogenic Decline in Skeletal Aging

doi: 10.1002/advs.77571

Figure Lengend Snippet: Enhanced CD38 ecto‐NADase activity in BMMs during skeletal aging impairs NMN availability to BMSCs. (a) qPCR analysis of Cd38 , Cdkn2a , Cdkn1a , Nos2 , Tnfα , IL1b , IL6 , Ym1 , Fizz1 , and Arg1 mRNA levels in bone marrow from 3‐ or 18‐month‐old WT and 18‐month‐old Sting ΔMφ mice ( n = 6 biological replicates). (b—d) Representative micro‐CT images (b) and quantitative analysis of BV/TV, Tb. N, Tb.Th, and Tb.Sp (c,d) from AAV9‐BMM‐shNC‐treated or AAV9‐BMM‐sh Cd38 ‐treated male mice ( n = 6 biological replicates). (e) WST‐8 analysis of NAD + levels in 3, 10, 18, and 24 M‐BMSCs ( n = 6 biological replicates). (f) WST‐8 analysis of NAD + levels in BMSCs under co‐culture conditions ( n = 6 biological replicates). (g) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice treated with PBS or 78c from 16‐ to 18‐month‐old ( n = 6 biological replicates). (h) WST‐8 analysis of NAD + levels in BMSCs from the bone marrow of mice injected with AAV9 for BMM‐specific overexpression of WT or Δ49 mouse Cd38 ( n = 6 biological replicates). Data are shown as mean ± SD.

Article Snippet: In parallel, 16‐month‐old male C57BL/6J mice received 78c (MedChemExpress, HY‐123999; 10 mg/kg) or PBS intraperitoneally 5 days per week for 8 weeks.

Techniques: Activity Assay, Analysis, Micro-CT, Co-culture Assay, Injection, Over Expression